BiPER Therapeutics: Funding, Investors & Team (Sep 2026)
A first-in-class pipeline of small compounds aimed at the cancer's overall metabolism is being created by BiPER Therapeutics. The company's main substance, BPR001, is a first-in-class small molecule therapy that targets the oncogenic protein BiP, which has been proven to play a significant role in cancer through the control of endoplasmic reticulum stress.
BiPER Therapeutics has raised $2.6M across 3 funding rounds on record, the most recent a Seed of $1.2M announced in Dec 2025.
That round is below the $4.7M median round size for Health Care companies tracked on FundedIQ over the last two years.
BiPER Therapeutics Company Profile and Key Stats
Latest funding round on record: Dec 2025.
BiPER Therapeutics Funding Rounds
BiPER Therapeutics raised $540k in an undisclosed round announced in Feb 2023.
1.8 years later, an undisclosed round of $840k was announced in Dec 2024.
1 years later, a Seed of $1.2M was announced in Dec 2025.
BiPER Therapeutics Founders and Leadership Team
Contact details for the BiPER Therapeutics team: 1 of 3 have an email address on file.
Start 14-day free trial →BiPER Therapeutics Funding Compared to Other Health Care Startups
BiPER Therapeutics' latest round of $1.2M is below the median round in Health Care. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like BiPER Therapeutics in Health Care and Strasbourg
Companies Similar to BiPER Therapeutics
Beams is a producer of medical devices for cancerology based on the use of particles β.
Padoa is an occupational health software firm that develops a tool for monitoring the health of employees.…
CILcare specializes in providing drug solutions for hearing and ear disorders.
MEDIAN Technologies develops medical imaging software and services dedicated to oncology clinical trials,…
noa is a digital fitness and wellness company that offers premium, structured training programs for strength,…
Semeia offers patient monitoring solution designed to support medical followup of patients, remotely and in…
Signadori Bio is the next-generation cellular immunotherapy for cancer cure.This has culminated in the…
Axomove is an e-wellbeing application that spends significant time in video actual activities.
Parallel helps coding agent works side by side with hospital teams to deliver faster and more accurate…
May Health has created a new solution for infertility caused by Polycystic Ovary Syndrome (PCOS) that is…
MedinCell is an injectable slow-release drug specialist company.
Charles helps men regain control over their daily health concerns by starting with their personal health.
BiPER Therapeutics Funding FAQs
What does BiPER Therapeutics do?
A first-in-class pipeline of small compounds aimed at the cancer's overall metabolism is being created by BiPER Therapeutics. The company's main substance, BPR001, is a first-in-class small molecule therapy that targets the oncogenic protein BiP, which has been proven to play a significant role in cancer through the control of endoplasmic reticulum stress.
How much funding has BiPER Therapeutics raised?
BiPER Therapeutics has raised $2.6M across 3 rounds on record. The most recent is a Seed of $1.2M announced in Dec 2025.
When did BiPER Therapeutics last raise funding?
BiPER Therapeutics' most recent funding round on record is a Seed of $1.2M, announced in Dec 2025.
Who founded BiPER Therapeutics?
FundedIQ lists Cyril Ronco (Founder), Rachid Benhida (Founder) at BiPER Therapeutics.
Who is the CEO of BiPER Therapeutics?
Mehdi Chelbi is listed as CEO at BiPER Therapeutics.
Where is BiPER Therapeutics headquartered?
BiPER Therapeutics is based in Strasbourg, Alsace, France.
How many employees does BiPER Therapeutics have?
BiPER Therapeutics is in the 11-50 employee band.
How does BiPER Therapeutics' funding compare to other Health Care startups?
BiPER Therapeutics' latest round of $1.2M is below the $4.7M median round size for Health Care companies on FundedIQ across 3,653 tracked companies over the last two years.
About FundedIQ's BiPER Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for BiPER Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.